Preparation method and application of bacteriophagic hemostatic agent

Abstract

The invention belongs to the field of biomedical materials, relates to a preparation method and application of a bacteriophagic hemostatic agent. The bacteriophagic hemostatic agent exhibits an RGD polypeptide by a bacteriophage exhibiting technology; the amino acid sequence of the polypeptide adopts a general formula as follows: Arg-Gly-Asp or other variants including three amino acids, namely Arg, Gly and Asp; the polypeptides is exhibited on the pVIII coat protein of bacteriophages. The bacteriophagic hemostatic agent has the following outstanding characteristics: (1) promotion of platelet activation: negatively charged platelets and fibrin in blood can be attracted, platelet adhesion can be increased and thrombosis can be promoted; (2) rapid hemostasis: through adhesion of a fibrin network in the blood to RGD bacteriophages, self-assembly and formation of a blood coagulating network can be accelerated, the hemostatic speed can be increased, the hemostatic effect can be promoted and the hemostatic mechanism can be improved; (3) wide application range: the bacteriophagic hemostatic agent is applicable to hemostasis of systemic blood loss, and especially provides a novel therapeutic method for treatment of internal bleeding of an organ.

Description

Preparation method and application of bacteriophage hemostatic agent Technical field The invention belongs to the field of biomedical materials, and relates to a preparation method and application of a bacteriophage hemostatic agent. Background technique Blood coagulation generally refers to the process in which blood changes from a flowing liquid state to a non-flowing gel state. It is mainly a process in which coagulation factors promote soluble fibrinogen in plasma to insoluble fibrin. The coagulation and anticoagulation systems existing in the normal blood circulation can balance each other, thereby ensuring the normal flow of blood. When the body has a wound due to an external force, the blood clotting factors and platelets can quickly stop the bleeding from the wound on the small wound (such as a minor cut). Recombinant coagulation factor, such as coagulation factor VII, is a traditional human blood coagulation factor and a representative of systemic hemostatic drugs. H...

AI Technical Summary

Problems solved by technology

However, because these drugs are chemically synthesized coagulants, they have the disadvantages of high toxicity, low coagulation efficiency, and limited sources, so their clinical application is limited.

Images